P&T Committees Will Be New Focus For Pharma Prosecutors
Executive Summary
Pharmacy & therapeutic committees will be a focus of scrutiny for federal prosecutors once the Medicare Part D benefit takes effect in 2006, Boston U.S. Attorney's Office White Collar Crime Section Chief Michael Loucks said Jan. 31 during CBI's Pharmaceutical Marketing Compliance Congress in Washington, D.C
You may also be interested in...
Medicare Rx Discounts Will Be “Comparable” To Private Plans, Medco Says
Medco expects its initial Medicare Rx contracts with manufacturers to include terms "comparable" to what it typically receives under its existing private market agreements
Medicare Rx Discounts Will Be “Comparable” To Private Plans, Medco Says
Medco expects its initial Medicare Rx contracts with manufacturers to include terms "comparable" to what it typically receives under its existing private market agreements
Medicare P&T Committees Can Consider Costs, But Only In Broad Context
Medicare prescription drug plan pharmacy & therapeutics committees must consider the overall economic impact of coverage decisions - not just pharmacy costs - if they use pharmacoeconomic data in their analyses, the Centers for Medicare & Medicaid Services states in its final rule implementing Title I of the Medicare Modernization Act